BUZZ-Jefferies trims CSL's PT as growth in key markets falls short of 'stellar'

Carlisle Companies Incorporated +4.16% Pre

Carlisle Companies Incorporated

CSL

361.70

361.70

+4.16%

0.00% Pre

** Brokerage Jefferies cuts Australian biopharmaceutical firm CSL's CSL.AX target price to A$212 from A$235, with a "buy" rating

** Brokerage says growth in CSL's key markets, immunoglobulin sales in the United States and albumin demand in China are not "stellar"

** Says demand concerns cast doubt on CSL's goal of strong second half of 2026

** Jefferies says immunoglobulin & albumin markets remain underpenetrated and should grow over the medium term

** 10 of 16 brokerages rate the stock "buy" or higher, while 6 rate it "hold"; their median PT is A$200 - LSEG data

** As of last close, stock had fallen 0.74%


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.